New research released before Pharmapack Europe has determined that the Basel region in Switzerland is the most attract destination in Europe for launching a new drug device company.
To attain this information, a survey was distributed to more than 280 global pharmaceutical executives, which asked them to identify the best location based on a range of factors.
Basel emerged as the clear leader, selected by one-third of respondents, outperforming Lombardy (18%), Catalunya (17%), the UK’s "Golden Triangle" (15%), and Baden-Württemberg in Germany (14%).
Although labour costs are higher in Basel, there is an 'unrivalled access to qualified personnel, as well as high-quality research firms'.
Switzerland was also selected as one of the best regions in which to build a new biomanufacturing facility.
Pharmapack Europe expects over 6,000 attendees and over 370 companies this year, with significant growth in early-stage companies participating. Its Start-Up Hub will host over 20 emerging companies, with increasing interest from German and Swiss executives seeking new development and licensing opportunities in device and packaging innovations.
The event, which takes places next month at the Paris Expo (January 22/23, 2025) is renowned as Europe’s premier pharmaceutical hub and empowers start-up innovators to meet with larger drug device and big pharma partners. Many of the breakthrough technologies in device design and sustainable packaging first gained industry attention at earlier editions of Pharmapack.
.
“As one of the few places where early-stage innovators can meet with investors and scale-up partners, we play a vital role in propagating drug delivery innovation,” commented Sherma Ellis-Daal, Brand Director at Pharmapack Europe.
“This research identifies the optimal locations for discovering and developing the next generation technologies for a novel device or new packaging - from concept to commercialisation. In fact, one of the major impediments to development success is simply having the access to the right partners to scale, which is why we are encouraging innovators from across these major European centres to attend the event.”
Pharmapack Europe expects over 6,000 attendees and over 370 companies this year, with significant growth in early-stage companies participating. Its Start-Up Hub will host over 20 emerging companies, with increasing interest from German and Swiss executives seeking new development and licensing opportunities in device and packaging innovations.
Stèfan Halbherr, CEO, InnoMedica a Swiss-based biotech and a Start-up Market innovator, attending Pharmapack to meet new clinical and commercial-scale partners for its nanocarriers filling technology, added: “It’s not surprising to us at all. Switzerland has a tremendous history of pharmaceutical innovation and highly qualified personnel. However, what is often underappreciated outside the country is the access to precision engineering available here. With many new devices and innovations targeting smaller patient cohorts for precision and personalised medicine applications, we need a fresh approach to device design and manufacturing flexibility."
"Switzerland offers an exceptional foundation in manufacturing precision machinery. For example, to develop our unique approach to nanoparticle device filling, we collaborated with a manufacturer specialising in the production of small, highly precise machinery traditionally used in watchmaking. Moving forward, you’ll see smaller companies leading the next generation of med-tech innovation by adopting techniques from other industries and applying them to Switzerland’s world-class biomedical infrastructure.”
The full results of the Pharmapack Report 2024 and Index will be released during the event on CPHI-online. Click here for a full breakdown of conference topics, or more information on the event please visit: www.pharmapackeurope.com/en